Intelligent responsive microcarriers have emerged as a promising class of biomaterials for therapeutic delivery and tissue regeneration, since they can respond to external stimuli and release the loaded drugs in an active manner. Among various available stimuli, near‐infrared (NIR) light is particularly attractive because it can penetrate biotic tissues with sufficient intensity and minimal damage. In this work, a kind of photoresponsive delivery microcarriers (PDMs) is developed using microfluidics. The microcarriers consist of NIR‐absorbing graphene oxide, thermosensitive poly(N‐isopropylacrylamide), and biocompatible gelatin methacrylate. Under NIR light, the PDMs exhibit an evident volume shrinkage and effectively trigger the drug release. After the NIR light is switched off, the shrunken microcarriers return to their original size. This reversible process can be stably repeated for many cycles. An in vitro experiment demonstrates that the NIR‐radiated PDMs can actively release vascular endothelial growth factors and improve the tube formation of human umbilical vein endothelial cells. The results from the in vivo experiment also show an obvious photothermal effect and superior therapeutic efficacy of these PDMs in a rat model of tissue defects. These features make the PDMs an excellent drug delivery system and represent a great potential for clinical applications in tissue repair.

Abdominal wall defect repair remains a major clinical need, and a particle-based controllable drug delivery system offers a solution to this problem. Here, we present a new type of hierarchically porous microparticles (HPMs) composed of poly(lactic-co-glycolic acid) (PLGA) and hollow mesoporous silica nanoparticles (HMSNs) for the delivery. The HPMs are generated by drying microfluidic emulsion templates of HMSNs-dispersed PLGA solution. The resultant HPMs have tailorable porous structures, that provide a three-hierarchy architecture for the controlled release of actives. The first hierarchy is formed for controlling the drug release via physical absorption as a result of the presence of the HMSNs in the HPMs. The second hierarchy channels with small pores scattered throughout the surface of the HPMs are formed during evaporation of the solvent. The third hierarchy with openings on the surface of the HPMs is formed as a result of the inner droplets leaking out of the double emulsion templates during the PLGA solidification. Thus, by manipulating the flow of solutions during the microfluidic emulsification, the porous structures of HPMs can be easily and precisely adjusted, and the loaded drugs are delivered at the required rate. These features of the HPMs make them ideal for repairing abdominal wall defects.

Patients with hepatic fibrosis (HF) have a high risk of developing liver cirrhosis and hepatocellular carcinoma, and there is an urgent need for preventive strategies to block this process. Previous studies have found that disordered inflammation and oxidative damage play important roles in HF progression, suggesting two attractive therapeutic targets. Herein, a new kind of bioinspired microcapsules with a core-shell structure is generated using microfluidics. Polydopamine nanoparticles (PDANPs), a synthetic analogue of natural melanin, are embedded in the polymer shell to provide antioxidative properties for these microcapsules. The aqueous core is used to encapsulate ketone body β-hydroxybutyrate (BHB), an energy metabolite recently known to have regulating effects of cellular signals involved in chronic inflammation. In a HF mouse model, the BHB-encapsulated PDANPs-embedded microcapsules (BHB-PDA-MCs) can not only decrease the severity of inflammatory response, but also the level of oxidative stress. As a result, this combinational strategy is demonstrated to prevent the activation of hepatic stellate cells, the accumulation of extracellular matrix, and the damage of hepatic lobules. These findings indicate that BHB-PDA-MCs can be a promising drug delivery system and have a synergistic effect on HF management.